Chesterbrook, PA-based AmerisourceBergen Corporation is one of the world’s largest pharmaceutical services companies, which focuses on providing drug distribution and related services to reduce healthcare costs and improve patient outcomes. AmerisourceBergen serves healthcare providers and pharmaceutical manufacturers in the pharmaceutical supply channel. The company has been actively pursuing acquisitions to strengthen its core areas and diversify.
Currently, AmerisourceBergen has a Zacks Rank #3 (Hold) but that could definitely change following its second-quarter fiscal 2017 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.)
Interestingly, AmerisourceBergen has an impressive track of comfortably beating estimates in each of the four trailing quarters. It has an average positive surprise of 7.66%. Below we have highlighted some of the key stats from this just-revealed announcement:
Earnings:AmerisourceBergen topped earnings in the reported quarter. Our consensus called for earnings of $1.71 per share, and the company reported adjusted earnings of $1.77 per share.
Revenue: AmerisourceBergen posted revenues of $37.1 billion in the reported quarter, which came significantly below our consensus estimate of $38.3 billion.
Key Stats: Revenue at the Pharmaceutical Distribution Services segment was $35.5 billion, up 4% on a year-over-year basis.
Coming to guidance, AmerisourceBergen expects adjusted earnings per share for full fiscal year 2017 in the band of $5.77 to $5.92, up from the previously provided range of $5.72–$5.92.
Of the recent highlights, the company has signed a new five-year agreement to supply pharmaceuticals to Express Scripts.
Share Performance:Shares have decreased 8.1% over the past 3 months, while the Zacks categorized Medical - Dental Supplies sub industry has gained 6.7%.
Check back later for our full write up on this AmerisourceBergen earnings report later!
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
Image: Bigstock
AmerisourceBergen (ABC) Q2 Earnings Beat, Sales Miss
Chesterbrook, PA-based AmerisourceBergen Corporation is one of the world’s largest pharmaceutical services companies, which focuses on providing drug distribution and related services to reduce healthcare costs and improve patient outcomes. AmerisourceBergen serves healthcare providers and pharmaceutical manufacturers in the pharmaceutical supply channel. The company has been actively pursuing acquisitions to strengthen its core areas and diversify.
Currently, AmerisourceBergen has a Zacks Rank #3 (Hold) but that could definitely change following its second-quarter fiscal 2017 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.)
Interestingly, AmerisourceBergen has an impressive track of comfortably beating estimates in each of the four trailing quarters. It has an average positive surprise of 7.66%. Below we have highlighted some of the key stats from this just-revealed announcement:
Earnings:AmerisourceBergen topped earnings in the reported quarter. Our consensus called for earnings of $1.71 per share, and the company reported adjusted earnings of $1.77 per share.
Revenue: AmerisourceBergen posted revenues of $37.1 billion in the reported quarter, which came significantly below our consensus estimate of $38.3 billion.
AmerisourceBergen Corporation (Holding Co) Price and EPS Surprise
AmerisourceBergen Corporation (Holding Co) Price and EPS Surprise | AmerisourceBergen Corporation (Holding Co) Quote
Key Stats: Revenue at the Pharmaceutical Distribution Services segment was $35.5 billion, up 4% on a year-over-year basis.
Coming to guidance, AmerisourceBergen expects adjusted earnings per share for full fiscal year 2017 in the band of $5.77 to $5.92, up from the previously provided range of $5.72–$5.92.
Of the recent highlights, the company has signed a new five-year agreement to supply pharmaceuticals to Express Scripts.
Share Performance:Shares have decreased 8.1% over the past 3 months, while the Zacks categorized Medical - Dental Supplies sub industry has gained 6.7%.
Check back later for our full write up on this AmerisourceBergen earnings report later!
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>